Q3 EPS Estimate for Soleno Therapeutics Decreased by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Research analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for Soleno Therapeutics in a report released on Wednesday, March 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $1.15 per share for the quarter, down from their previous forecast of $1.24. HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q4 2026 earnings at $1.56 EPS, FY2026 earnings at $4.65 EPS, Q1 2027 earnings at $1.58 EPS, Q2 2027 earnings at $1.78 EPS, Q3 2027 earnings at $1.96 EPS and Q4 2027 earnings at $2.18 EPS.

A number of other research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a report on Tuesday, January 13th. Wolfe Research set a $60.00 target price on Soleno Therapeutics in a report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Finally, Zacks Research downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $106.85.

Soleno Therapeutics Stock Performance

Soleno Therapeutics stock opened at $39.68 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. Soleno Therapeutics has a 12 month low of $32.63 and a 12 month high of $90.32. The company has a fifty day moving average price of $41.61 and a two-hundred day moving average price of $52.23. The company has a market cap of $2.05 billion, a PE ratio of 172.53 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million.

Institutional Investors Weigh In On Soleno Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. bought a new position in Soleno Therapeutics in the 2nd quarter valued at about $25,000. Danske Bank A S bought a new position in shares of Soleno Therapeutics in the third quarter valued at approximately $27,000. Global Retirement Partners LLC increased its stake in shares of Soleno Therapeutics by 519.0% during the fourth quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock valued at $29,000 after acquiring an additional 519 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in Soleno Therapeutics during the third quarter worth approximately $37,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Soleno Therapeutics in the fourth quarter worth approximately $38,000. 97.42% of the stock is currently owned by institutional investors.

Soleno Therapeutics News Roundup

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Q4 results topped expectations — Soleno reported Q4 revenue of $91.7M (above Street estimates) and beat on EPS, a near-term catalyst supporting the stock’s rise. TD Cowen maintained a Buy on the name after the print. Article Title
• Positive Sentiment: HC Wainwright kept a Buy rating and $100 target — The firm also raised several near-term EPS forecasts (Q1 2026 to $0.93 from $0.88; Q2 2026 to $1.02 from $1.00) and set an aggressive FY2027 view ($7.50), signaling confidence in longer-term revenue/earnings growth drivers.
• Neutral Sentiment: Analyst detail shows a mixed revision pattern — while Wainwright raised some short-term estimates and projected strong 2027 results, the firm simultaneously adjusted other quarterly numbers; the net effect is a bullish price target but with recalibrated 2026 timing.
• Negative Sentiment: Wainwright trimmed several 2026 quarter estimates and lowered FY2026 slightly — Q3 2026 was cut to $1.15 (from $1.24), Q4 2026 to $1.56 (from $1.70), and FY2026 to $4.65 (from $4.82). These downgrades suggest potential near-term execution or timing risks that could cap upside until 2026 cadence is clearer.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.